PureTech HealthPRTCY +1.49%62 Altman Z-Score is 1.10 as of Jun. 24, 2026, which is 52% below its 10-year median of 2.30. GuruFocus rates PRTCY with a GF Score™ of 62/100 and a GF Value™ of $70.09 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 935 Biotechnology companies, PureTech Health ranks worse than 60% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.11 is in distress zone. This implies bankruptcy possibility in the next two years.
PureTech Health has a Altman Z-Score of 1.10, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for PureTech Health's Altman Z-Score or its related term are showing as below:
PRTCY'
s Altman Z-Score Range Over the Past 10 Years
Min: -0.47 Med: 2.3 Max: 4.58
Current: 1.11
During the past 13 years, PureTech Health's highest Altman Z-Score was 4.58. The lowest was -0.47. And the median was 2.30.
PureTech Health (OTCPK:PRTCY) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
PureTech Health Altman Z-Score Related Terms
PureTech Health Altman Z-Score Historical Data
* Premium members only.
The historical data trend for PureTech Health's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRTCY vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, PureTech Health's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where PureTech Health's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
PureTech Health's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.4838
+
1.4
*
-0.1444
+
3.3
*
-0.1218
+
0.6
*
1.8579
+
1.0
*
0.0087
=
1.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
PureTech Health (PRTCY) has a Altman Z-Score of 1.10 as of Jun. 24, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on PureTech Health and its competitors. This is 52% below median its historical median of 2.30. According to the industry distribution chart, PureTech Health ranks #561 out of 935 companies in the Biotechnology industry, placing it in the top 60%.
Is PureTech Health's Altman Z-Score too high?
PureTech Health's current Altman Z-Score of 1.10 is 52% below median its 10-year median of 2.30. The Biotechnology industry median Altman Z-Score is 2.64. PureTech Health's value of 1.10 is 58.3% below this industry median. Based on the distribution chart, PureTech Health ranks #561 out of 935 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #561 out of 935 companies for Altman Z-Score. This places PureTech Health in the lower half of its industry. The industry median Altman Z-Score is 2.64. PureTech Health's value of 1.10 is 58.3% below this benchmark. While the company's 10-year median is 2.30 vs. the industry median of 2.64, PureTech Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.64, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current Altman Z-Score of 1.10 is 58.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on PureTech Health and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current Altman Z-Score is 1.10, which is 52% below median its own 10-year median of 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current Altman Z-Score is 1.10, which is 52% below median its 10-year median of 2.30 and 58.3% below the Biotechnology industry median of 2.64. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For PureTech Health (PRTCY), the current Altman Z-Score is 1.10 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
Altman Z-Score: 1.10 (52% below median its 10-year median of 2.30)
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
Industry Position: 58.3% below the Biotechnology median (#561 of 935)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
